UPCC 45421 Phase I/II study to reduce post-transplantation cyclophosphamide dosing for older or unfit patients undergoing bone marrow transplantation for hematologic malignancies

Brief description of study

Certain blood cancers are treat blood or bone marrow transplants. Sometimes the donor cells attack the recipient's body, called GVHD. Cyclophosphamide helps reduce the risk and severity of GVHD .Researchers want to learn if using a lower dose of cyclophosphamide may reduce the drug's side effects while maintaining its effectiveness.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions:
Medical Research
Age: - 99 Years
Gender: All

Updated on 11 May 2022. Study ID: 850688

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).